Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,076 matching trials from the live ClinicalTrials.gov search.
Conditions
Cystic Fibrosis
Interventions
MP-376 (Levofloxacin Solution for Inhalation), TIS (Tobramycin Inhalation Solution)
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
99
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 86 more
Not yet recruiting Not applicable Interventional

Rethinking Early Airway Clearence Therapies

NCT07696338
Conditions
Cystic Fibrosis (CF)
Interventions
As-needed hypertonic saline (HS), Twice daily hypertonic saline (HS), As-needed dornase alfa (DA), Daily dornase alfa (DA)
Other
Lead sponsor
Nicole Hamblett
Other
Eligibility
3 Years to 16 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more
Conditions
Hepatopulmonary Syndrome
Interventions
pentoxifylline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Cystic Fibrosis
Interventions
Cavosonstat, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 42 more
Completed No phase listed Observational Accepts healthy volunteers

Breath Condensate Study in Patients With Cystic Fibrosis.

NCT02056132
Conditions
Cystic Fibrosis
Interventions
Exhaled Breath Condensate
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Cystic Fibrosis
Interventions
Tezacaftor/Ivacaftor, Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Conditions
Lung Diseases, Interstitial, Pulmonary Fibrosis
Interventions
CT-V, Metabolites
Device · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Royal Oak, Michigan
Conditions
Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Not listed
Lead sponsor
Pulmonary Fibrosis Foundation
Other
Eligibility
18 Years to 99 Years
Enrollment
2,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BMS-986278, BMS-986278 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
1,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
70
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 59 more
Conditions
Idiopathic Pulmonary Fibrosis, Fibrosis, Idiopathic Interstitial Pneumonias, Pathologic Processes, Lung Diseases, Interstitial, Lung Diseases, Respiratory Tract Diseases
Interventions
CC-90001, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
40 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
21
States / cities
Loma Linda, California • Los Angeles, California • Sacramento, California + 16 more
Conditions
Pulmonary Fibrosis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cystic Fibrosis, Quality of Life
Interventions
Massage Therapy
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Blood Flow and Vascular Function in Cystic Fibrosis

NCT02057458
Conditions
Cystic Fibrosis
Interventions
Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Pneumocystis Carinii Pneumonia
Interventions
Antibiotics only, Antibiotics + Corticosteroids, Corticosteroids + antibiotics
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Not applicable Interventional Accepts healthy volunteers

Assessing Mucociliary Clearance and Airway Liquid Volume in the CF Airway

NCT00248755
Conditions
Cystic Fibrosis
Interventions
mucociliary clearance scan
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Lung Diseases, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 100 Years
Enrollment
3,459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Detection of Early Idiopathic Pulmonary Fibrosis

NCT03457935
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
blood samples
Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Lung Movement With Computed Tomography (CT)

NCT03068091
Conditions
Interstitial Lung Disease
Interventions
Chest CT, Pulmonary Function Testing
Device · Diagnostic Test
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more
Completed Not applicable Interventional Results available

Advancing Symptom Alleviation With Palliative Treatment

NCT02713347
Conditions
Heart Failure, Pulmonary Disease, Chronic Obstructive, Emphysema, Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
ADAPT Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pulmonary Fibrosis, Hypertension, Pulmonary
Interventions
Sildenafil Citrate, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Cystic Fibrosis Related Bone Disease: the Role of CFTR

NCT01549314
Conditions
Cystic Fibrosis Related Bone Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts